Logo image of LUMO

LUMOS PHARMA INC (LUMO) Stock Fundamental Analysis

NASDAQ:LUMO - Nasdaq - US55028X1090 - Common Stock - Currency: USD

4.34  0 (0%)

After market: 4.34 0 (0%)

Fundamental Rating

3

LUMO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 550 industry peers in the Biotechnology industry. The financial health of LUMO is average, but there are quite some concerns on its profitability. While showing a medium growth rate, LUMO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year LUMO has reported negative net income.
In the past year LUMO has reported a negative cash flow from operations.
In the past 5 years LUMO always reported negative net income.
In the past 5 years LUMO always reported negative operating cash flow.
LUMO Yearly Net Income VS EBIT VS OCF VS FCFLUMO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of -199.97%, LUMO is doing worse than 90.44% of the companies in the same industry.
Looking at the Return On Equity, with a value of -710.54%, LUMO is doing worse than 81.95% of the companies in the same industry.
Industry RankSector Rank
ROA -199.97%
ROE -710.54%
ROIC N/A
ROA(3y)-52.36%
ROA(5y)-41.28%
ROE(3y)-70.33%
ROE(5y)-54.18%
ROIC(3y)N/A
ROIC(5y)N/A
LUMO Yearly ROA, ROE, ROICLUMO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

LUMO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LUMO Yearly Profit, Operating, Gross MarginsLUMO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5K -10K -15K

More info and screens

6

2. Health

2.1 Basic Checks

LUMO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LUMO has less shares outstanding
The number of shares outstanding for LUMO has been increased compared to 5 years ago.
LUMO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LUMO Yearly Shares OutstandingLUMO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M
LUMO Yearly Total Debt VS Total AssetsLUMO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -19.20, we must say that LUMO is in the distress zone and has some risk of bankruptcy.
LUMO has a worse Altman-Z score (-19.20) than 86.02% of its industry peers.
LUMO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -19.2
ROIC/WACCN/A
WACC11.91%
LUMO Yearly LT Debt VS Equity VS FCFLUMO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

2.3 Liquidity

LUMO has a Current Ratio of 2.66. This indicates that LUMO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.66, LUMO is doing worse than 69.38% of the companies in the same industry.
LUMO has a Quick Ratio of 2.66. This indicates that LUMO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.66, LUMO is doing worse than 67.79% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.66
Quick Ratio 2.66
LUMO Yearly Current Assets VS Current LiabilitesLUMO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for LUMO have decreased by -6.98% in the last year.
Looking at the last year, LUMO shows a very strong growth in Revenue. The Revenue has grown by 29.71%.
LUMO shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -30.34% yearly.
EPS 1Y (TTM)-6.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.46%
Revenue 1Y (TTM)29.71%
Revenue growth 3Y117.26%
Revenue growth 5Y-30.34%
Sales Q2Q%10271.43%

3.2 Future

The Earnings Per Share is expected to grow by 40.16% on average over the next years. This is a very strong growth
LUMO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 53.11% yearly.
EPS Next Y8.71%
EPS Next 2Y21.42%
EPS Next 3Y18.96%
EPS Next 5Y40.16%
Revenue Next Year385.58%
Revenue Next 2Y-14.99%
Revenue Next 3Y112.7%
Revenue Next 5Y53.11%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
LUMO Yearly Revenue VS EstimatesLUMO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2028 2029 2030 2031 200M 400M 600M
LUMO Yearly EPS VS EstimatesLUMO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 10 -10 20 -20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LUMO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LUMO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LUMO Price Earnings VS Forward Price EarningsLUMO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LUMO Per share dataLUMO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as LUMO's earnings are expected to grow with 18.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.42%
EPS Next 3Y18.96%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LUMO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LUMOS PHARMA INC

NASDAQ:LUMO (12/11/2024, 8:00:00 PM)

After market: 4.34 0 (0%)

4.34

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/dmh
Earnings (Next)N/A N/A
Inst Owners25.37%
Inst Owner Change0%
Ins Owners14.94%
Ins Owner Change0%
Market Cap37.54M
Analysts78
Price Target9.88 (127.65%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.49%
Min EPS beat(2)-15.49%
Max EPS beat(2)26.47%
EPS beat(4)2
Avg EPS beat(4)0.92%
Min EPS beat(4)-15.49%
Max EPS beat(4)26.47%
EPS beat(8)5
Avg EPS beat(8)4.45%
EPS beat(12)8
Avg EPS beat(12)7.15%
EPS beat(16)11
Avg EPS beat(16)9.56%
Revenue beat(2)2
Avg Revenue beat(2)147.42%
Min Revenue beat(2)43.53%
Max Revenue beat(2)251.32%
Revenue beat(4)3
Avg Revenue beat(4)11605.7%
Min Revenue beat(4)-46.54%
Max Revenue beat(4)46174.5%
Revenue beat(8)6
Avg Revenue beat(8)5867.96%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-52.97%
PT rev (3m)-55.46%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.85%
EPS NY rev (1m)0.4%
EPS NY rev (3m)-4.9%
Revenue NQ rev (1m)-91.21%
Revenue NQ rev (3m)-94.6%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-23.84%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 17.03
P/FCF N/A
P/OCF N/A
P/B 7.64
P/tB 7.64
EV/EBITDA N/A
EPS(TTM)-4.29
EYN/A
EPS(NY)-2.2
Fwd EYN/A
FCF(TTM)-3.66
FCFYN/A
OCF(TTM)-3.66
OCFYN/A
SpS0.25
BVpS0.57
TBVpS0.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -199.97%
ROE -710.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-52.36%
ROA(5y)-41.28%
ROE(3y)-70.33%
ROE(5y)-54.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.66
Quick Ratio 2.66
Altman-Z -19.2
F-Score4
WACC11.91%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)0%
Cap/Sales(5y)0%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.46%
EPS Next Y8.71%
EPS Next 2Y21.42%
EPS Next 3Y18.96%
EPS Next 5Y40.16%
Revenue 1Y (TTM)29.71%
Revenue growth 3Y117.26%
Revenue growth 5Y-30.34%
Sales Q2Q%10271.43%
Revenue Next Year385.58%
Revenue Next 2Y-14.99%
Revenue Next 3Y112.7%
Revenue Next 5Y53.11%
EBIT growth 1Y-2.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-19.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-19.08%
OCF growth 3YN/A
OCF growth 5YN/A